FR2990617A1 - Installation de traitement des donnees pour un dispositif d'anesthesie - Google Patents
Installation de traitement des donnees pour un dispositif d'anesthesie Download PDFInfo
- Publication number
- FR2990617A1 FR2990617A1 FR1354350A FR1354350A FR2990617A1 FR 2990617 A1 FR2990617 A1 FR 2990617A1 FR 1354350 A FR1354350 A FR 1354350A FR 1354350 A FR1354350 A FR 1354350A FR 2990617 A1 FR2990617 A1 FR 2990617A1
- Authority
- FR
- France
- Prior art keywords
- concentration
- hypnotic
- hypnotics
- opioid
- volatile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010002091 Anaesthesia Diseases 0.000 title abstract description 36
- 230000037005 anaesthesia Effects 0.000 title abstract description 36
- 230000000147 hypnotic effect Effects 0.000 abstract description 109
- 230000000694 effects Effects 0.000 abstract description 43
- 239000003326 hypnotic agent Substances 0.000 abstract description 35
- 238000001990 intravenous administration Methods 0.000 abstract description 31
- 229940035674 anesthetics Drugs 0.000 abstract description 25
- 239000003193 general anesthetic agent Substances 0.000 abstract description 25
- 230000003444 anaesthetic effect Effects 0.000 abstract description 20
- 238000012821 model calculation Methods 0.000 abstract description 10
- 238000004364 calculation method Methods 0.000 abstract description 8
- 238000009434 installation Methods 0.000 abstract description 5
- 238000005259 measurement Methods 0.000 abstract description 3
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 23
- 229960004134 propofol Drugs 0.000 description 23
- 230000007704 transition Effects 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 9
- 238000002576 laryngoscopy Methods 0.000 description 9
- 229940005483 opioid analgesics Drugs 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000037007 arousal Effects 0.000 description 6
- 229960002078 sevoflurane Drugs 0.000 description 5
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 206010013710 Drug interaction Diseases 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003983 inhalation anesthetic agent Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 229960003394 remifentanil Drugs 0.000 description 2
- 238000004481 total suppression of sideband Methods 0.000 description 2
- 101001137525 Homo sapiens Nucleolin Proteins 0.000 description 1
- 101100521345 Mus musculus Prop1 gene Proteins 0.000 description 1
- 102100021010 Nucleolin Human genes 0.000 description 1
- 108700017836 Prophet of Pit-1 Proteins 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002483 combined anesthetic agent Substances 0.000 description 1
- 239000002869 intravenous anesthetic agent Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/16886—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body for measuring fluid flow rate, i.e. flowmeters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/104—Preparation of respiratory gases or vapours specially adapted for anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
- A61M16/18—Vaporising devices for anaesthetic preparations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/1005—Preparation of respiratory gases or vapours with O2 features or with parameter measurement
- A61M2016/102—Measuring a parameter of the content of the delivered gas
- A61M2016/1035—Measuring a parameter of the content of the delivered gas the anaesthetic agent concentration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/502—User interfaces, e.g. screens or keyboards
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Fluid Mechanics (AREA)
- Vascular Medicine (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Abstract
Description
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102012009617.8A DE102012009617B4 (de) | 2012-05-15 | 2012-05-15 | Datenverarbeitungseinrichtung für eine Anästhesievorrichtung |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2990617A1 true FR2990617A1 (fr) | 2013-11-22 |
FR2990617B1 FR2990617B1 (fr) | 2017-10-06 |
Family
ID=49510770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR1354350A Active FR2990617B1 (fr) | 2012-05-15 | 2013-05-15 | Installation de traitement des donnees pour un dispositif d’anesthesie |
Country Status (5)
Country | Link |
---|---|
US (1) | US9744299B2 (fr) |
JP (1) | JP3185202U (fr) |
CN (1) | CN103418067B (fr) |
DE (1) | DE102012009617B4 (fr) |
FR (1) | FR2990617B1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9849241B2 (en) | 2013-04-24 | 2017-12-26 | Fresenius Kabi Deutschland Gmbh | Method of operating a control device for controlling an infusion device |
EP4309566A1 (fr) * | 2021-03-18 | 2024-01-24 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | Procédé d?indication de la profondeur d?une anesthésie, dispositif d?alerte de profondeur d?anesthésie et machine d?anesthésie |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2325834T3 (es) * | 2003-02-28 | 2009-09-21 | Ym Biosciences Inc. | Sistema de administracion de opioides. |
DE102004050717B8 (de) * | 2004-10-19 | 2006-02-23 | Dräger Medical AG & Co. KGaA | Anästhesievorrichtung |
CN101472631A (zh) * | 2006-06-21 | 2009-07-01 | 伯尔尼大学 | 用于控制麻醉给药的系统 |
US20080234322A1 (en) * | 2007-03-20 | 2008-09-25 | University Of Utah | Methods and apparatus for drug modeling and displaying drug models |
DE102007038975A1 (de) * | 2007-06-30 | 2009-01-02 | Dräger Medical AG & Co. KG | Verfahren und Vorrichtung zum Überwachen eines Patienten während der Narkose und zum Bestimmen eines gemeinsamen Effekts mehrerer Anästhetika |
EP2194474A1 (fr) * | 2008-11-28 | 2010-06-09 | General Electric Company | Présentation d'administration de médicament et agencement pour la présentation d'administration de médicament |
-
2012
- 2012-05-15 DE DE102012009617.8A patent/DE102012009617B4/de active Active
-
2013
- 2013-05-15 US US13/894,655 patent/US9744299B2/en active Active
- 2013-05-15 CN CN201310179222.XA patent/CN103418067B/zh active Active
- 2013-05-15 JP JP2013002706U patent/JP3185202U/ja not_active Expired - Lifetime
- 2013-05-15 FR FR1354350A patent/FR2990617B1/fr active Active
Also Published As
Publication number | Publication date |
---|---|
DE102012009617B4 (de) | 2020-03-26 |
US9744299B2 (en) | 2017-08-29 |
DE102012009617A1 (de) | 2013-11-21 |
FR2990617B1 (fr) | 2017-10-06 |
CN103418067A (zh) | 2013-12-04 |
JP3185202U (ja) | 2013-08-08 |
US20130306063A1 (en) | 2013-11-21 |
CN103418067B (zh) | 2016-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Olanow et al. | Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study | |
Sivarao et al. | 40 Hz auditory steady-state response is a pharmacodynamic biomarker for cortical NMDA receptors | |
Stocchi et al. | Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study | |
Laurenzi et al. | Effects of carbohydrate counting on glucose control and quality of life over 24 weeks in adult patients with type 1 diabetes on continuous subcutaneous insulin infusion: a randomized, prospective clinical trial (GIOCAR) | |
Manson et al. | Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations | |
Ataga et al. | Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia | |
Montgomery et al. | Reduction of brain dopamine concentration with dietary tyrosine plus phenylalanine depletion: an [11C] raclopride PET study | |
Vilay et al. | Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis | |
Sobngwi et al. | Day-to-day variation of insulin requirements of patients with type 2 diabetes and end-stage renal disease undergoing maintenance hemodialysis | |
Devuyst et al. | Tolerability of aquaretic-related symptoms following tolvaptan for autosomal dominant polycystic kidney disease: results from TEMPO 3: 4 | |
KR102397974B1 (ko) | 약물동역학 약물 투약 요법의 제공 | |
Antonini et al. | Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease | |
Wen et al. | Increasing of intrathecal CSF excitatory amino acids concentration following morphine challenge in morphine-tolerant rats | |
Li et al. | Sirolimus is effective for primary relapsed/refractory autoimmune cytopenia: a multicenter study | |
Alffenaar et al. | Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis | |
Bolhuis et al. | Clarithromycin significantly increases linezolid serum concentrations | |
Roozekrans et al. | Benefit versus severe side effects of opioid analgesia: novel utility functions of probability of analgesia and respiratory depression | |
Signor et al. | Spermidine improves fear memory persistence | |
Strunk et al. | Single-and multiple-dose pharmacokinetics of ethambutol and rifampicin in a tuberculosis patient with acute respiratory distress syndrome undergoing extended daily dialysis and ECMO treatment | |
FR2990617A1 (fr) | Installation de traitement des donnees pour un dispositif d'anesthesie | |
Auyanet et al. | Measurement of foveal thickness by optical coherence tomography in adult haemodialysis patients with diabetic nephropathy | |
Falcone et al. | Daptomycin serum levels in critical patients undergoing continuous renal replacement | |
Eslam et al. | Target site pharmacokinetics of linezolid after single and multiple doses in diabetic patients with soft tissue infection | |
Sarı et al. | Efficacy and quality of life assessment in the use of subcutaneous immunoglobulin treatment for children with primary immunodeficiency disorder | |
Grada et al. | Reduced blood-brain barrier penetration of acne vulgaris antibiotic sarecycline compared to minocycline corresponds with lower lipophilicity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 3 |
|
TQ | Partial transmission of property |
Owner name: INSELSPITAL BERN, CH Effective date: 20160226 Owner name: DRAGERWERK AG & CO. KGAA, DE Effective date: 20160226 |
|
PLFP | Fee payment |
Year of fee payment: 4 |
|
PLSC | Publication of the preliminary search report |
Effective date: 20170210 |
|
PLFP | Fee payment |
Year of fee payment: 5 |
|
PLFP | Fee payment |
Year of fee payment: 6 |
|
PLFP | Fee payment |
Year of fee payment: 7 |
|
PLFP | Fee payment |
Year of fee payment: 8 |
|
PLFP | Fee payment |
Year of fee payment: 9 |
|
PLFP | Fee payment |
Year of fee payment: 10 |
|
PLFP | Fee payment |
Year of fee payment: 11 |
|
PLFP | Fee payment |
Year of fee payment: 12 |